drugset / Trial / NCT05742841

EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

NCT05742841

Phase 4 Completed 22 enrolled Wake Forest University Health Sciences
NaSingle-groupOpen-labelPrevention

Summary

The EMERALD intervention involves 1) ordering an Emergency Department (ED) lipid panel, 2) calculating 10-year Atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations, 3) prescribing a moderate- or high-intensity statin if applicable, and 4) referring patients to outpatient care (primary care, preventive cardiology, or general cardiology, depending on risk level).

Timeline

Start
2023-03-08
Primary completion
2023-06-01
Completion
2023-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 10 mg
Subject Rosuvastatin Small molecule 40 mg

Indications